Neurol. praxi. 2018;19(4):276-278 | DOI: 10.36290/neu.2018.106

Pharmacotherapy of multiple sclerosis in light of the necessary costs associated with prescribing the indicated drug

MUDr. Jiří Slíva, Ph.D.
Ústav farmakologie 3. LF UK, Praha

Multiple sclerosis is a serious neurological disease with the potential to significantly interfere with the patient's daily activities. Inrecent years, there has been an unpredictable increase in the supply of medicines with innovative mechanisms of action that offerthe chance to patients for the significantly longer sustained quality of life. However, their prescription also brings some additionalcosts in terms of the requirement for ongoing patient investigation / monitoring, etc. The aim of this article is to find out and defacto draw the differences in this area among the registered drugs of the individual treatment lines.

Keywords: multiple sclerosis, sclerosis multiplex, disability, costs

Published: September 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Slíva J. Pharmacotherapy of multiple sclerosis in light of the necessary costs associated with prescribing the indicated drug. Neurol. praxi. 2018;19(4):276-278. doi: 10.36290/neu.2018.106.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    LMm_References

    1. Alvarez Ayuso L, Rodriguez Marrodan B, Blasco Quilez MR, Garcia-Merino JA, Sanchez Guerrero A. Economic impact of the new oral treatments for multiple sclerosis. Neurologia 2018. doi: 10.1016/j.nrl.2017.10.015. [Epub ahead of print]. Go to original source... Go to PubMed...
    2. Blahova Dusankova J, Kalincik T, Dolezal T, Kobelt G, Havrdova E. Cost of multiple sclerosis in the Czech Republic: the COMS study. Mult. Scler. 2012; 18: 662-668. Go to original source... Go to PubMed...
    3. Ernstsson O, Gyllensten H, Alexanderson K, Tinghog P, Friberg E, Norlund A. Cost of illness of multiple sclerosis - a systematic review. PLoS. One. 2016; 11: e0159129. Go to original source... Go to PubMed...
    4. Gyllensten H, Wiberg M, Alexanderson K, Friberg E, Hillert J, Tinghog P. Comparing costs of illness of multiple sclerosis in three different years: a population-based study. Mult. Scler. 2018; 24: 520-528. Go to original source... Go to PubMed...
    5. Havrdova E, Kobelt G, Berg J, Capsa D, Gannedahl M, Dolezal T. New insights into the burden and costs of multiple sclerosis in Europe: results of the Czech Republic. Mult. Scler. 2017; 23: 41-52. Go to original source... Go to PubMed...
    6. Landfeldt E, Castelo-Branco A, Svedbom A, Lofroth E, Kavaliunas A, Hillert J. Personal income before and after Diagnosis of multiple sclerosis. Value. health 2018; 21: 590-595. Go to original source... Go to PubMed...
    7. Stawowczyk E, Malinowski KP, Kawalec P, Mocko P. The indirect costs of multiple sclerosis: systematic review and meta-analysis. Expert Rev Pharmacoecon. Outcomes Res 2015; 15: 759-786. Go to original source... Go to PubMed...
    8. VZP. Klient s roztroušenou sklerózou stojí VZP v průměru 122 tisíc ročn?. https://www.vzp.cz/o-nas/aktuality/klient-s-roztrousenou-sklerozou-stoji-vzp-v-prumeru-122-tisic-rocne. 2017.

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.